Actively Recruiting

Phase Not Applicable
Age: 18Years - 99Years
All Genders
NCT05762302

The Impact of MeMed BV® on Management of Patients With Suspected Lower Respiratory Tract Infections (LRTI) in the Emergency Department (ED) and Urgent Care Center (UCC) ("JUPITER" TRIAL)

Led by MeMed Diagnostics Ltd. · Updated on 2026-01-21

1316

Participants Needed

10

Research Sites

160 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is a Prospective, multi-center study enrolling adults subjects presented to the ED/Urgent care, with symptoms consistent with lower respiratory infection (LRTI). The reason of this study is to demonstrate the MeMed BV can help clinicians make decisions about using antibiotics in patients with lower respiratory track infections and see how it would impact clinical outcomes, antibiotics use, hospitalizations, ED clinicians find ways to improve health and medical care.

CONDITIONS

Official Title

The Impact of MeMed BV® on Management of Patients With Suspected Lower Respiratory Tract Infections (LRTI) in the Emergency Department (ED) and Urgent Care Center (UCC) ("JUPITER" TRIAL)

Who Can Participate

Age: 18Years - 99Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Written informed consent must be obtained from the patient or legal guardian.
  • Age 18 years or older.
  • Current illness lasting 7 days or less.
  • Fever of 37.86C (1006F) or higher, or feeling feverish, recorded at least once in the past 7 days.
  • Clinical suspicion of bacterial or viral lower respiratory tract infection with symptoms like new or worsening cough, sputum production, shortness of breath, or abnormal lung sounds.
  • Clinician plans to prescribe antibiotics based on available data.
Not Eligible

You will not qualify if you...

  • Use of systemic antibiotics within 72 hours before enrollment.
  • Having inflammatory diseases such as IBD, SLE, rheumatoid arthritis, Kawasaki disease, or other vasculitis.
  • Having congenital immune deficiency.
  • Known or suspected infections with mycobacterial, parasitic, or fungal pathogens.
  • Known HIV, HBV, or HCV infection.
  • Major surgery, trauma, or burns within the last 7 days.
  • Pregnancy (self-reported or medically confirmed).
  • Active cancer diagnosed or treated within the past six months or hematological cancer not in remission.
  • Severe illnesses affecting life expectancy or quality of life like end-stage kidney or liver disease or severe COPD.
  • Clinician intends to hospitalize the patient.
  • Suspected other infections like urinary tract infection, cellulitis, or gastroenteritis.
  • Current treatment with immune-suppressive or immune-modulating therapies including high-dose steroids, monoclonal antibodies, IVIG, cyclosporine, cyclophosphamide, tacrolimus, azathioprine, methotrexate, or interferons.
  • Considered unsuitable for the study by the study team.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 10 locations

1

University of Florida-Jacksonville

Jacksonville, Florida, United States, 32209

Actively Recruiting

2

University of Kansas Medical Center

Kansas City, Kansas, United States, 66160

Actively Recruiting

3

Maimonides Medical Center

Brooklyn, New York, United States, 11219

Actively Recruiting

4

Stony Brook University Hospital

Stony Brook, New York, United States, 11794

Actively Recruiting

5

Philadelphia Thomas Jefferson ED

Philadelphia, Pennsylvania, United States, 19107

Actively Recruiting

6

Medical University South Carolina

Charleston, South Carolina, United States, 29425

Actively Recruiting

7

UT Southwestern Medical Center

Dallas, Texas, United States, 75390

Actively Recruiting

8

MCW

Milwaukee, Wisconsin, United States, 53226

Actively Recruiting

9

Carmel Medical Center

Haifa, North, Israel

Actively Recruiting

10

Lin Medical Center

Haifa, Israel

Not Yet Recruiting

Loading map...

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

DIAGNOSTIC

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

The Impact of MeMed BV® on Management of Patients With Suspected Lower Respiratory Tract Infections (LRTI) in the Emergency Department (ED) and Urgent Care Center (UCC) ("JUPITER" TRIAL) | DecenTrialz